Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

FEops closes €6m series B financing

FEops, a leader in personalized computer modeling for structural heart interventions, announced today that it has secured a 6 million euros investment, led by Valiance, and joined by existing investors Capricorn and PMV.

The funding will be used to aggressively implement the company’s product roadmap, centered around FEops HEARTguide, and drive commercial adoption in the fast-growing market for transcatheter valve therapies.

FEops HEARTguide proprietary array of products use advanced computer simulations to provide clinicians and valve manufacturers with first-ever insights into the interaction between valve and specific patient anatomy – preoperatively.

Such insights have tremendous power to accelerate research and development of novel valve-based solutions, as well as ultimately improve clinical outcomes in real-world hospital settings

Backed by strong preclinical data, FEops HEARTguide presents a prime opportunity to integrate valve design with patient-specific testing, and to do so virtually, cost-effectively and in a clinically meaningful way.

Showcasing a pipeline of simulation products for structural heart, including TAVI (Transcatheter Aortic Valve Implantation), mitral and tricuspid valve replacement, FEops has the ambition to enable wider adoption of transcatheter approaches by minimizing the risk of life-threatening complications while reducing cost, and thus improve patient care.

Our first commercial product, TAVIguideTM, is currently the only CE-marked technology that can predict how an aortic valve implant will interact with the patient-specific anatomy and provide guidance for personalized device size selection and position,” said Matthieu De Beule, Ph.D., co-Founder and CEO of FEops.

“This Series B capital will enable us to scale commercial operations, deliver on our pipeline of simulation tools for structural heart and promptly realize the significant opportunity in the growing transcatheter valve market.”

“The shift towards transcatheter-based solutions has been a game changer in TAVI and is rapidly expanding to soon dominate the structural heart space,” said Jan Pensaert, Founder and CEO of Valiance.

Privately held FEops, headquartered in Gent, Belgium, has developed a proprietary system to improve transcatheter valve procedures based on personalized computer simulations. Its first product, TAVIguide™, is currently the only CE-marked technology on the market that predicts how a TAVI implant will interact with the patient-specific aortic anatomy and thus provide clinically meaningful insights in the personalized device size selection and position.

The product displays that will be available exclusively to growers and shippers from International Paper’s five bulk facilities include corrugated bulk bins.